Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

Induction therapy approaches in recent years have evolved, now utilizing triple or quadruple drug regimens in the majority of patients. By combining anti-CD38 antibodies, proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and steroids, patients achieve longer remissions with their first- and second-line therapies but also become refractory to most or all three major drug classes earlier. For patients who are refractory to at least 3 of the commonly administered PIs and IMiDs, occurring after 2 lines of therapy in many, the median overall survival is only 5 months. Elderly, frail pati

Trial Details

NCT ID
NCT06827860
Phase
PHASE2
Sponsor
Larysa Sanchez
Status
RECRUITING
Cancer Type
Relapsed/Refractory Multiple Myeloma
Interventions
  • Talquetamab
  • Daratumumab
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Documented multiple myeloma as defined by the criteria below:
  • Multiple myeloma diagnosis according to the IMWG diagnostic criteria
  • Measurable disease at screening as assessed by central laboratory, defined by at least 1 of the following:
  • Serum M-protein level ≥0.5 g/dL (central laboratory)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Relapsed/Refractory Multiple Myeloma Trials on Trialify →